Comparison of Lidocaine and Remifentanil for the Effect on Responses to the Endotracheal Tube During Emergence From General Anesthesia

This study has been completed.

Sponsor:

Information provided by:

Yonsei University

ClinicalTrials.gov Identifier:

NCT01082458

First received: March 4, 2010

Last updated: November 18, 2010

Last verified: November 2010

History of Changes

Tracking Information
First Received Date ^ICMJE	March 4, 2010
Last Updated Date	November 18, 2010
Start Date ^ICMJE	February 2010
Primary Completion Date	July 2010 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE (submitted: March 5, 2010)	Comparison of lidocaine and remifentanil for the effect on responses to the endotracheal tube during emergence from general anesthesia [ Designated as safety issue: No ] The incidence and the grade of cough during emergence from general anensthesia between remifentanil TCI group and lidocaine IV administration group.
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	Complete list of historical versions of study NCT01082458 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Comparison of Lidocaine and Remifentanil for the Effect on Responses to the Endotracheal Tube During Emergence From General Anesthesia
Official Title ^ICMJE	Comparison of Lidocaine and Remifentanil for the Effect on Responses to the Endotracheal Tube During Emergence From General Anesthesia
Brief Summary	Target concentration infusion(TCI) of remifentanil (2.0ng/ml) suppresses the cough induced by endotracheal tube more effectively than intravenous administration of lidocaine (1.5mg/kg).
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Not Provided
Study Design ^ICMJE	Primary Purpose: Prevention
Condition ^ICMJE	Thyroidectomy
Intervention ^ICMJE	Drug: remifentanil / lidocaine Remifentanil TCI group : target controlled infusion of 2.0ng/ml of remifentanil on end of surgery. Lidocaine IV group : Intravenous administration of 1.5mg/kg of lidocaine on end of surgery.
Study Arm (s)	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	67
Completion Date	July 2010
Primary Completion Date	July 2010 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Females older than 20 years old Exclusion Criteria: Patients with acute or chronic respiratory disease, hypertension, gastro-esophageal reflux disease, having preoperative sedatives or mucolytics, and current smoker.
Gender	Female
Ages	20 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Korea, Republic of

Administrative Information
NCT Number ^ICMJE	NCT01082458
Other Study ID Numbers ^ICMJE	4-2009-0519
Has Data Monitoring Committee	Yes
Responsible Party	Jung-Lim Lee / Assistant Professor, Anesthesiology and Pain Medicine
Study Sponsor ^ICMJE	Yonsei University
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Yonsei University
Verification Date	November 2010
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top